Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • dinepat203 dinepat203 Apr 24, 2014 8:18 AM Flag

    SRPT-IS A SCAM WITH PROMISE – NO TRIALS UNDERWAY– NO PAST TRIALS RESULTS DECLARED

    To file NDA you must first produce legitimate results through FDA-controlled/recommended Clinical trials.
    However records at CLINICALTRIALS.GOV shows AT PRESENT THERE IS NO SINGLE CLINICAL TRIALS underway which can lead to NDA process.
    1 Completed Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients
    Condition: Duchenne Muscular Dystrophy
    Intervention: Drug: AVI-4658 (Eteplirsen)
    ClinicalTrials.gov Identifier:
    NCT01396239
    First received: July 8, 2011
    Last updated: January 22, 2013
    Last verified: January 2013
    More Information
    No publications provided by Sarepta Therapeutics

    2 Active, not recruiting Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
    Condition: Duchenne Muscular Dystrophy
    Intervention: Drug: AVI-4658 (Eteplirsen)

    3 Completed Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients
    Condition: Duchenne Muscular Dystrophy
    Intervention: Drug: AVI-4658 for Injection
    ClinicalTrials.gov Identifier:
    NCT00844597
    First received: December 24, 2008
    Last updated: April 22, 2011
    Last verified: April 2011

    • PTC Therapeutics, Inc.
    Ataluren for nmDMD: Phase 2b clinical trial complete; Confirmatory Phase 3 clinical trial initiated
    Ataluren for nmCF: Phase 3 trial complete; Confirmatory Phase 3 clinical trial planned to enroll trial sites in the second half of 2013 and dose first patient in the first half of 2014
    currently have ongoing collaborations with Roche and the SMA Foundation for the development and commercialization of compounds for the treatment of spinal muscular atrophy
    4 Completed Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy
    Condition: Duchenne Muscular Dystrophy
    Intervention: Drug: AVI-4658 (PMO)
    ClinicalTrials.gov Identifier:
    NCT0

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SRPT
32.03+0.03(+0.09%)Jul 28 4:00 PMEDT